On this page
Published: · Updated:
Key Takeaways
- Choose between specialist services, internal-team tooling, integrated engineering, and hospital risk management based on the work you need.
- Compare written deliverables, testing boundaries, assigned practitioners, and manufacturer responsibilities rather than vendor rankings.
- Keep statutory Section 524B duties separate from FDA guidance recommendations and device-specific standards applicability.
- Ask how testing, SBOM evidence, threat modeling, and postmarket maintenance connect across your device lifecycle.
- Agree pricing, scope changes, retesting, capacity, and support after filing in writing.
Choose a medical device cybersecurity provider by matching its delivery model to your team's needs. Compare who performs testing, who writes submission evidence, and who maintains records after release. Ask for redacted work samples, named practitioners, device-specific scope, and written commercial terms. A platform, engineering partner, hospital risk tool, and specialist services firm solve different problems. Your manufacturer team retains submission decisions, risk acceptance, and product release approval.
Patient safety starts with engineering evidence, not a vendor ranking. A medical device cybersecurity provider should connect the device's threats, controls, test results, and maintenance processes to the work your team actually performs. A familiar brand or a long feature list does not establish that fit.
The FDA's February 3, 2026 final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, provides recommendations for this evidence. Section 524B creates statutory duties for covered cyber-device submissions. Keep those two sources distinct when evaluating a proposal.
Start with your intended use, system architecture, software build, submission pathway, existing records, and internal capacity. Then give each shortlisted provider the same inputs. Written answers make services and platform proposals comparable without assuming every provider performs the same work.
Why This Matters
Cybersecurity affects clinical function, availability, and the integrity of device data. A proposal that covers only a web application may leave firmware, wireless interfaces, update mechanisms, or connected services outside its scope. Those omissions need an explicit owner and a documented decision, not an assumption that another vendor will handle them.
The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, February 3, 2026 final guidance, discusses secure development and submission evidence. Section 524B separately requires covered cyber-device submissions to include an SBOM and plans and processes addressing cybersecurity vulnerabilities. The manufacturer remains responsible even when a provider prepares supporting documents or operates monitoring tools.
Standards literacy matters, but a list of acronyms is not evidence of applicability. Ask how IEC 81001-5-1 secure lifecycle activities, IEC 62304 software processes, ISO 14971 safety risk management, and ANSI/AAMI SW96 cybersecurity risk management relate to your device and existing QMS. Do not treat every standard or recommended activity as a universal legal requirement.
Keep track-record evidence in its proper context. Blue Goat's approved statement is: 275+ FDA submissions supported, zero cybersecurity rejections. That describes prior support work, not a promise about a future submission. Ask every provider what its figures count and how it protects client confidentiality when sharing examples.
Which Provider Model Matches the Work You Need?
Choose a delivery model before comparing individual firms. The useful distinctions from side-by-side provider comparisons are responsibility, outputs, and internal workload, not an unsupported ranking of named vendors.
| Delivery model | Work to clarify in the proposal | Internal responsibility to plan for |
|---|---|---|
| Specialist cybersecurity services | Agreed testing, threat modeling, SBOM analysis, risk assessment, and submission documentation | Supply device inputs, review evidence, implement fixes, and approve decisions |
| Product-security platform | Inventory, binary analysis, vulnerability triage, workflow, exports, and any included expert services | Operate the tool, review findings, reconcile inventories, and assemble engineering evidence |
| Integrated engineering partner | Device or software development plus separately defined cybersecurity work | Review design ownership, testing separation, conflicts, and reporting responsibilities |
| Hospital or third-party risk platform | Vendor questionnaires, procurement evidence, inventory, and healthcare-network risk workflows | Distinguish hospital procurement reviews from manufacturer-side submission work |
| General application-security consultancy | Explicit web, mobile, API, network, firmware, hardware, and reporting scope | Identify any medical-device evidence or interfaces outside the engagement |
A firm's label does not establish its current capability. Some providers combine tooling and expert services. Ask who performs each activity, what you receive, and which tasks remain with your team.
Can Services and Platforms Work Together?
Services and platforms can be complementary when their handoffs are defined. A platform-generated SBOM still needs review against the device configuration and available source, build, binary, and supplier evidence. A vulnerability alert still needs triage, an affected-release decision, and a record of the manufacturer's response.
Name the owner for each handoff. Confirm export formats, access controls, confidential handling, data retention, and what happens when a license or service engagement ends. Tool access should not be confused with ownership of the engineering decisions.
What Should a Comparable Provider Proposal Include?
A comparable proposal identifies the work, assigned people, evidence, inputs, exclusions, and commercial terms. Ask each provider to respond to the same questions rather than compare unrelated package names.
| Ask every provider | Evidence to request |
|---|---|
| Who writes the cybersecurity documents, and who assembles the submission attachments? | Named deliverables and a responsibility map |
| Who performs hands-on testing, and how is testing separated from design? | Assigned practitioners, conflict disclosures, methods, and review arrangements |
| Which device builds, firmware, interfaces, applications, and services are covered? | A scope boundary with versions, assumptions, and exclusions |
| If AI is involved, are you testing our AI features or using AI to run tests? | Model and interface coverage, tool-use disclosure, human review, confidentiality controls, and verified results |
| How do findings connect to threats, controls, requirements, and patient harm? | A redacted report and traceability example |
| What does SBOM work include beyond an automated export? | Inventory reconciliation, supplier follow-up, review, and release linkage |
| What happens after remediation or an FDA cybersecurity question? | Written retest, review-round, and response-support terms |
| Who maintains the evidence after release? | Maintenance triggers, process owners, and separately scoped postmarket support |
| Who is assigned, when can work start, and what inputs are needed? | Named delivery leads, capacity arrangements, dependencies, and agreed dates |
| What is fixed, what is hourly, and what changes the fee? | A statement of work, exclusions, and change-control terms |
Ask whether delivery uses employees, subcontractors, or a combination. Confirm who can access confidential builds and records. Ask how continuity is handled if an assigned practitioner becomes unavailable.
How Do You Choose FDA Cybersecurity Services for Your Device?
Choose FDA cybersecurity services by identifying the evidence your manufacturer team needs, not by treating the phrase as a certification. Medical device cybersecurity includes secure development, threat modeling, security testing, component evidence, and postmarket processes. FDA cybersecurity work adds the pathway-specific documentation and review context for a submission.
| Buyer need | Scope to request | Decision your team retains |
|---|---|---|
| FDA cybersecurity requirements for a covered cyber device | Section 524B applicability review, statutory duties, and a separate guidance-based evidence map | Regulatory applicability and submission decisions |
| Medical device cybersecurity consulting | Review of existing records, evidence gaps, QMS connections, and assigned deliverables | Procedure approval and engineering implementation |
| Medical device penetration testing | Device versions, interfaces, test access, findings, and retest evidence | Remediation and residual-risk acceptance |
| A broader premarket cybersecurity package | Agreed threat model, SBOM, testing, architecture, and supporting documentation | Review and submission of the final evidence |
Ask each provider to distinguish legal duties from recommendations in the FDA's February 3, 2026 final guidance. A claimed FDA cybersecurity specialty does not mean the provider is approved by the agency. A generic connected-device report does not establish medical-device coverage without clinical context and a defined system boundary.
Compare medical device cybersecurity consulting with the FDA premarket cybersecurity package. Consulting can address a defined evidence gap; it does not automatically include testing or every submission document.
How Do You Evaluate Medical Device Testing Depth?
Evaluate testing against your actual architecture and adversary assumptions. Relevant scope can include firmware, debug access such as JTAG or UART, update mechanisms, wireless interfaces, mobile applications, APIs, cloud services, and medical protocols. Not every technique belongs in every engagement; ask for the rationale and exclusions.
An automated scan or binary-analysis report is not the same deliverable as hands-on penetration testing. Ask which activities are automated, which are performed by practitioners, and how findings are verified. Request evidence of the tested configuration, reproduction steps, observed results, limitations, and remediation verification.
Check the separation between design and testing. An integrated partner may perform both, but the proposal should explain its review arrangements and conflicts. A separate testing firm is another option; neither arrangement removes the manufacturer's responsibility to evaluate the evidence.
For scope and reporting detail, see medical device penetration testing services.
Use the Black-Box vs White-Box Pen Test comparison to discuss tester access, limitations, and the rationale for the proposed method. A method label alone does not establish device coverage.
What Does “AI Penetration Testing” Mean in a Proposal?
AI penetration testing can mean testing an AI-enabled product or using AI tools to conduct tests. Ask the provider to separate those meanings. An automated web test does not establish coverage of inference endpoints, model updates, training-data access, or LLM tool permissions.
For AI-enabled devices, request model versions, accessible components, relevant attack scenarios, test data, and explicit exclusions. Ask who verifies findings and whether confidential builds, patient data, or prompts leave the agreed environment. Clinical performance validation is separate from security testing.
Review AI/ML Medical Device Security for a device-specific scope and the 510(k) AI SaMD Penetration Testing Case Study for published testing evidence. That case demonstrates its documented scope, not every AI attack technique or device modality.
How Should Threat Modeling and Risk Evidence Connect?
Threat modeling should follow the device's boundaries, data flows, interfaces, and clinical use. Ask for an example that connects identified threats to security requirements, controls, and test evidence. A threat list alone does not explain control coverage or residual risk.
See also: Medical Device Cybersecurity: 2026 Best Practices Guide, What Is MedTech? MedTech vs Medical Device vs Life Sciences, and CVSS Score for Medical Devices: How to Calculate and Use It.
STRIDE classifies threats; it does not score risk. Keep security exploitability and security impact separate from patient-harm severity. The manufacturer supplies safety severity from its ISO 14971 hazard analysis and owns risk acceptance.
Ask how architecture changes, component updates, and new vulnerability information trigger review. The maintained threat model and risk records should identify responsible owners and controlled versions. See medical device threat modeling for device-specific scope.
Compare STRIDE vs PASTA for threat-identification approaches and ISO 14971 vs AAMI SW96 for the relationship between security and safety risk evidence. Ask providers to explain their method without claiming that the FDA mandates a particular threat-modeling technique.
Which Submission and Lifecycle Evidence Should You Request?
Request evidence appropriate to the device, pathway, and agreed engagement. Relevant outputs can include secure-development descriptions, security architecture views, a threat model, security risk assessment, SBOM, testing evidence, labeling information, and vulnerability-management plans. Define who prepares each output and how your team reviews it.
Section 524B applies to cyber devices in covered marketing submissions. Its statutory duties must be evaluated separately from nonbinding guidance recommendations. A vendor contract does not transfer the manufacturer's duties or authorize a provider to make submission, risk-acceptance, or release decisions.
Ask how attachments map to the applicable eSTAR template or other submission structure. Avoid claims that a document format guarantees acceptance or eliminates review questions. Review the FDA premarket cybersecurity deliverables and eSTAR map for evidence categories.
What Should SBOM and Postmarket Support Cover?
SBOM work should connect inventory evidence to a controlled device configuration and release. Ask about source and binary coverage, supplier components, support information, second-person review, and how unknowns are recorded. Confirm whether you receive machine-readable outputs and whether your tooling can import them.
Use SPDX vs CycloneDX SBOM formats to check output versions, required fields, and conversion limits. The file format does not establish the inventory's completeness. Review AAMI SW96 vs TIR57 and IEC 62304 vs IEC 81001-5-1 when comparing standards claims and procedure scope.
Postmarket scope should identify vulnerability intake, triage, affected-release decisions, updates, disclosure, and links to change control. Confirm who performs each activity and which services are separately contracted. An ongoing platform license does not itself establish that someone owns these decisions.
If procedures need revision, review cybersecurity QMS integration. Your quality team approves and implements its SOPs and retains the records.
How Do You Compare Pricing, Retests, and Response Support?
Compare total agreed scope rather than a headline fee. Ask whether pricing is fixed, hourly, subscription-based, or a combination. Record device access, travel, licenses, review rounds, retesting, and support after filing as included work or explicit exclusions.
Retesting terms should explain the configuration, findings, and remediation evidence covered. Response-support terms should identify whether they apply to a package the provider authored or to a letter received before the engagement. Do not assume a standard testing quote includes a full documentation package or ongoing support.
Dates should depend on the actual inputs, device access, and agreed capacity. Ask for start and delivery dates in the statement of work rather than infer them from firm size. A short schedule does not establish evidence quality or a regulatory outcome.
How Do You Build a Shortlist Without Vendor Rankings?
Use the same device description and evidence checklist for each candidate. Review public claims against current proposals and redacted samples. Do not infer that a capability is absent simply because a website does not advertise it, or classify a firm permanently by an old product description.
Record unresolved questions before signing. A suitable shortlist may include a specialist firm, an engineering partner, or a platform with expert support, depending on internal capacity. Hospital risk-management software addresses a different buyer need and should not be treated as a substitute for manufacturer-side engineering evidence.
For a consulting-specific scope checklist, see the Medical Device Cybersecurity Consulting Buyer's Guide.
How Blue Goat Cyber Approaches This
Blue Goat publishes this guide and provides medical device cybersecurity services. It is a first-party explanation of how to evaluate scope, not an independent ranking of providers. Our engineers' credentials include CISSP, OSCP, and military red-team experience.
Blue Goat performs agreed penetration testing, threat modeling, SBOM work, security risk assessment, and cybersecurity documentation. You can scope an individual service or the FDA premarket cybersecurity package. The manufacturer supplies inputs, reviews evidence, implements fixes, and retains submission, risk-acceptance, and release decisions.
Fees are fixed after scoping. Unlimited retests and response support follow the agreed engagement terms. For premarket packages we deliver: If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
QMS procedure work and postmarket support are separately agreed, not automatically included in every package. We can work alongside your engineering partner or internal product-security tools. The proposal defines deliverables, responsibilities, dependencies, and handoffs before work begins.
Frequently Asked Questions
How do I choose a medical device cybersecurity provider?
Match the delivery model to the work and internal capacity you have. Compare written scope, named practitioners, redacted evidence samples, device and interface coverage, pricing, and support terms. Ask who writes each document and who maintains it after release. The manufacturer retains submission decisions, fixes, risk acceptance, and release approval regardless of the provider selected.
Can a product-security platform replace a penetration test?
A platform may support inventory, binary analysis, vulnerability monitoring, or workflow. Those outputs are not automatically a hands-on penetration test report. Ask whether practitioner-led testing is included, which interfaces and builds are exercised, and how findings are verified. Decide the required testing scope from your architecture, threat model, and applicable evidence needs rather than the platform label.
Do I need both a services firm and a platform?
Not necessarily. The right arrangement depends on device complexity, internal staff, existing tools, and maintenance needs. A services firm may prepare agreed evidence while a platform supports ongoing inventory or triage. If you use both, name the owners of exports, review, configuration changes, and vulnerability decisions. Avoid duplicate contracts without a clear responsibility map.
Does a provider own our FDA submission or QMS?
No. A provider can draft documents, conduct security testing, and support responses within agreed scope. The manufacturer reviews and approves its submission, owns its QMS, implements fixes, accepts risk, and authorizes release. Section 524B duties remain with the manufacturer. Confirm these boundaries in the proposal and in the document-control and approval processes used by your team.
What should I ask about fees and support after filing?
Ask whether fees are fixed, hourly, or subscription-based and what changes them. Identify included deliverables, review rounds, retesting, travel, and dependencies. Request written terms for cybersecurity questions after filing, including which authored packages are covered. Ask separately about postmarket maintenance and QMS procedure revisions. Neither ongoing support nor a regulatory outcome should be assumed from the initial fee.
CTA
Discuss your device architecture, current evidence, and internal capacity with Blue Goat. Request a scoped FDA premarket cybersecurity engagement. For premarket packages we deliver: If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
Sources
About the author
Christian Espinosa, MBA · Founder & CEO, Blue Goat Cyber
U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Blue Goat track record: 275+ FDA submissions supported, zero cybersecurity rejections. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.
Sources & references
Primary sources cited in this article. Links open in a new tab.